^
BIOMARKER:
IDH2 mutation
i
Other names: IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
Entrez ID:
Related biomarkers:
IDH2 mutation
AML
enasidenib
Sensitive
:
A1
IDH2 mutation
AML
venetoclax
Sensitive
:
A2
IDH2 mutation
AML
cytarabine
Resistant
:
B
IDH2 mutation
Glioma
temozolomide gel
Sensitive
:
B
IDH2 mutation
Glioma
PCV
Sensitive
:
B
IDH2 mutation
Glioma
BGB-290
Sensitive
:
C2
IDH2 mutation
Cholangiocarcinoma
dasatinib
Sensitive
:
C2
IDH2 mutation
Leukemia
venetoclax
Sensitive
:
C2
IDH2 mutation
Glioma
TG02
Sensitive
:
C3
IDH2 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive
:
C3
IDH2 mutation
AML
venetoclax + RO5503781
Sensitive
:
C3
IDH2 mutation
Peripheral T-cell Lymphoma
copanlisib
Sensitive
:
C3
IDH2 mutation
CMML
venetoclax
Sensitive
:
C3
IDH2 mutation
AML
venetoclax + ABBV-621
Sensitive
:
C3
IDH2 mutation
AML
CFI-400945
Sensitive
:
C3
IDH2 mutation
AML
venetoclax + midostaurin
Resistant
:
C3
IDH2 mutation
AML
venetoclax + gilteritinib
Resistant
:
C3
IDH2 mutation
AML
venetoclax + sorafenib
Resistant
:
C3
IDH2 mutation
GBM
temozolomide gel
Sensitive
:
C3
IDH2 mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant
:
C3
IDH2 mutation
Anaplastic Astrocytoma
PCV
Sensitive
:
C3
IDH2 mutation
Sarcoma
olaparib
Sensitive
:
C3
IDH2 mutation
AML
venetoclax + enasidenib
Sensitive
:
C4
IDH2 mutation
Cholangiocarcinoma
AZD0530
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our